Cartalax: A Research Overview of the AED Cartilage Bioregulator

Cartalax is one of the Khavinson “bioregulator” peptides — a family of ultra-short sequences from a single, long-running Russian research program — and it calls for the same caution as the others in that group, plus one more. Beyond the usual issue (a thin, largely single-source preclinical literature), Cartalax has an unusual and important problem: the public sources do not agree on which molecule it even is. An honest overview has to start there, because nothing else means much until the identity is pinned down.

This summary describes what the authoritative chemical record and the published literature actually report about Cartalax — including where they conflict — along with its proposed mechanism and regulatory status. It describes findings as they appeared in their experimental systems. It is not dosing guidance, medical advice, or a recommendation for use.

What Cartalax Is — and the Identity Confusion

According to the public chemical databases, Cartalax is a tripeptide with the sequence alanine-glutamic acid-aspartic acid (Ala-Glu-Asp, AED), also referenced by the code T-31. Its cataloged formula is C₁₂H₁₉N₃O₈ with a molar mass of about 333 g/mol, consistent with three amino acids (Cartalax chemical identity (AED tripeptide), reference entry). That is the most authoritative identity available, and it is the one this article uses.

Here is the caution, and it is a real one. Vendor and blog descriptions of “Cartalax” are inconsistent and, in places, appear to confuse it with other Khavinson peptides. Some sources list it as a tetrapeptide “Ala-Glu-Asp-Lys (AEDK)” with a molar mass of about 461 g/mol — but that mass matches a different peptide in the same family (Livagen, KEDA), suggesting a mix-up. Others attach the sequence “AEDG” (Ala-Glu-Asp-Gly) to Cartalax, but AEDG is the documented sequence of Epitalon, a separate compound (AEDG = Epitalon, confirmed in peer-reviewed literature, PMC). The practical takeaway: material sold as “Cartalax” may not refer to a single, consistent molecule across vendors, and that ambiguity should temper any confident claim made about it.

It was developed within the program led by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, which proposed isolating short peptide sequences specific to particular tissues and synthesizing them as tissue-targeted “bioregulators.” Cartalax is positioned within that program as the cartilage-associated member.

Proposed Mechanism

The proposed mechanism is shared across the Khavinson family and is a notable claim in its own right. Rather than acting on cell-surface receptors, these ultra-short peptides are proposed to enter the cell, reach the nucleus, and interact directly with DNA or chromatin — binding regulatory regions to influence which genes are transcribed. For Cartalax specifically, the proposed targets are genes that govern the cartilage matrix, such as those encoding collagen and proteoglycans, with the aim of shifting chondrocytes from a matrix-degrading state toward a matrix-building one.

Two things should be held in mind about this model. It is mechanistically interesting and internally coherent. It is also a hypothesis advanced largely within the originating research program, and the direct DNA-binding mode of action of these peptides is not well established in the broader molecular biology literature. “Proposed” is the operative word throughout.

The Evidence Base — Thin and Single-Source

This is where expectations need the firmest grounding. Even by the standards of the bioregulator family, the Cartalax-specific literature is sparse.

The available studies are preclinical — cell culture and animal models — and come overwhelmingly from the originating program and its collaborators, published largely in a narrow set of journals (for example, work on bioregulator peptides in Advances in Gerontology). Much of what is cited for “Cartalax” in product copy actually describes the broader peptide-bioregulator category rather than this specific compound, and even sympathetic summaries acknowledge that Cartalax research is limited and that its precise binding sites and molecular interactions remain unclear (acknowledgment of limited Cartalax-specific evidence).

There are no controlled human clinical trials establishing efficacy for cartilage, joint, or any other indication. Claims of “cartilage regeneration” or “joint repair” describe a hypothesis and some animal-level observations, not demonstrated human outcomes — and they rest on a compound whose very identity is reported inconsistently across sources. The honest characterization is a lightly evidenced research compound within a single-program hypothesis, not an established cartilage therapy.

• Findings attributed to Cartalax come from cell and animal studies, overwhelmingly from one research program.
• Much cited evidence concerns the bioregulator class generally, not this specific compound.
• No controlled human clinical trials support any indication, and the molecule’s identity is reported inconsistently.

Regulatory Status

The status below reflects mid-2026 and may change; verify against current sources before relying on it. Cartalax is not FDA-approved for any indication in the United States. It is sold as a research-grade compound for laboratory use only and is, by its labeling, not intended for human consumption (research-use-only status, vendor disclosure). Like other Khavinson peptides, it sits outside the FDA’s 503A peptide-compounding review and has no established clinical or compounded access pathway in U.S. practice; in some markets, these bioregulators are sold within supplement-like categories, which is a regulatory classification rather than evidence of efficacy.

Why Cartalax Appears in Research Discussions

The conceptual appeal mirrors the rest of the family: the intriguing idea that an ultra-short, tissue-associated peptide might act as a gene-level regulator of the tissue it came from — here, cartilage. For researchers curious about that hypothesis, Cartalax is the cartilage-labeled entry point. But the accurate framing is unusually heavily qualified for this one: a compound with an inconsistently reported identity, a thin and largely single-source preclinical record, an unproven mechanism, and no clinical validation. Genuine scientific curiosity is reasonable; confidence in any specific claim is not warranted by the current evidence.

For deeper reading, the primary chemical records and the limited primary literature cited here are the best starting points. Related short-peptide and bioregulator topics are collected in our peptide research library, which gathers reference material on the wider class of compounds discussed here.

A note on the evidence base: Independent, peer-reviewed evidence in English is limited; much of the available literature on Cartalax originates from the originating research group (the Khavinson program) and has not been widely replicated. The citations below reflect that literature, and readers should weigh it accordingly.